Abu Dhabi: SARS-CoV-2 has evolved to acquire mutations on the spike protein—the part of the virus that protrudes from its surface and latches onto cells to infect them that enhance the coronavirus’ ability to bind to human cells or evade antibodies. A new study from the Centers for Genomics and Systems Biology at New York University (NYU) Abu Dhabi and New York University uses computational modeling to assess the biological significance of spike protein mutations, uncovering versions of the virus that bind more tightly or resist antibodies and offering a promising public health surveillance tool.
The study, which appears in the Journal of Molecular Biology, also suggests that these mutations on the spike protein are a key reason for the virus’ rapid spread in parts of the world.
New and more transmissible COVID-19 variants have emerged in recent months, fueling surges of cases in countries like India and Brazil. As a public health measure, rapid surveillance methods are needed to determine the biological effects of variants and to help anticipate emerging infectious viral strains. But monitoring new variants is no small task; genome sequencing shows that the SARS-CoV-2 spike protein alone, for example, has about 5,000 possible variants.
“Screening such a large set of variants poses a tremendous challenge for conventional experimental methods,” said Senior Research Scientist at NYU’s Center for Genomics and Systems Biology and the study’s lead author Hin Hark Gan. “An advantage of computer-based modeling is that a hundred mutations can be readily assessed in a few days.”
Gan and his colleagues turned to a computational method that models how the SARS-CoV-2 spike protein recognizes the ACE2 receptor—a protein on the surface of many types of cells—to gain entry into host cells. Studies of coronaviruses indicate that spike-ACE2 recognition is the basis for infection.
The researchers focused on screening the mutations located where the spike protein and ACE2 receptor meet. They assessed 1,003 mutation combinations in the spike and ACE2 proteins, including those resulting in the fast-spreading spike variants that have originated in Brazil, South Africa, the U.K., and India.
Their systematic assessment of variants uncovered that spike mutations that bind tightly to the ACE2 receptor occur in two clusters or mutation “hotspots” on the binding interface. These hotspots are located in structurally flexible regions, indicating that mutations that increase binding effectively reprogrammed the spike conformation to enhance its recognition of the ACE2 receptor.
The researchers also looked at single, double, and triple mutations in the critical spike interface region, which make up some of the recently emerged infectious variants. Their modeling analysis suggests the spike variants S477N, N501Y, and S477N + E484K and E484K + N501Y—fast-spreading double mutants found in Brazil, South Africa, the U.S., and U.K.—have increased binding to the ACE2 receptor relative to the original coronavirus that emerged in Wuhan.
Gan and colleagues observed that the E484K and E484Q mutations found in some recent fast-spreading variants are not only predicted to bind more strongly to ACE2 but have also been shown to confer antibody resistance. Neutralizing antibodies are produced in response to viral infection and target different sites on the spike protein to prevent the virus from invading host cells. This prompted the researchers to look at another factor contributing to viral transmission: antibody resistance of individual spike mutations.
In particular, the variant circulating in India has two mutations in the spike interface region: L452R and E484Q. This variant is not predicted to bind to the ACE2 receptor more tightly than the virus that originated in Wuhan, likely because the individual mutations have opposing effects (the L452R mutation binds less easily while the E484Q mutation binds more easily). Strikingly, however, both of these mutations are strong antibody evaders, a scenario not found in other recent variants.
“As more of antibody target sites become resistant to antibodies due to viral mutations, the efficacy of existing antibodies and vaccines may diminish,” added Gan. “This scenario is a likely cause for the rapid spread of the variant in India.”
The study not only provides explanations for the coronavirus’ rapid spread—both mutations that enhance binding to human cells and help evade antibodies—but also points to a promising predictive tool in the ongoing public health fight against SARS-CoV-2.
“Our computational modeling method can be used as a real-time surveillance tool to screen for emerging infectious COVID-19 variants. It allows for a more timely response to emerging outbreaks and could be used to guide the development of new vaccines,” said Professor of Biology at NYU, Faculty Director of Bioinformatics at NYU Abu Dhabi, and the study’s senior author Kristin C. Gunsalus.
In addition to Gan and Gunsalus, study authors include Alan Twaddle in the Gunsalus group at NYU and NYU Abu Dhabi, as well as Benoit Marchand in NYU Abu Dhabi’s High Performance Computing Group.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
